Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.
Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.
Bruker (BRKR) Q3 Earnings Beat Estimates, '22 Sales View Down
by Zacks Equity Research
Despite ongoing macroeconomic headwinds, Bruker (BRKR) registers strong demand for differentiated high-value scientific instruments and life science solutions.
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
by Zacks Equity Research
Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
by Zacks Equity Research
Tandem Diabetes (TNDM) defers $0.6 million of United States pump sales as a result of Tandem Choice.
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results benefit from the solid performance of the Pharmaceutical segment.
Exact Sciences (EXAS) Q3 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Exact Sciences (EXAS) registers robust revenues from the Screening and Precision Oncology segments in Q3.
Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed
by Zacks Equity Research
Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).
Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
AMN Healthcare (AMN) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter 2022 results benefit from segmental growth.
LHC Group's (LHCG) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.
Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.
Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.
Inogen (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.
Nevro (NVRO) Q3 Earnings Beat Estimates, 2022 View Revised
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.
QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised
by Zacks Equity Research
QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.
Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.
CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up
by Zacks Equity Research
Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.